SUPN +23%Here we see a strong impulse and long correction during almost 2 years. Now it’s breakout and going higher.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.2USD
1.32 MUSD
607.52 MUSD
52.62 M
About Supernus Pharmaceuticals, Inc.
Sector
CEO
Jack A. Khattar
Headquarters
Rockville
Website
Employees (FY)
652
Founded
2005
FIGI
BBG00JVRK635
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
SUPN going upWhat used to be a resistance now a support.
Plus an inverse head & shoulders.
Plus positive news: “Supernus said that a Phase 3 trial 'met the primary endpoint ... compared to placebo in improving the symptoms of ADHD.'"
Going long anticipating 30’s where MA200 is and then maybe higher.
With tight s
$SUPN Supernus Pharmaceuticals Bull flag This share reports earnings today. Downtrend broken and building what looks like a bull flag. Targets 29.40 and 33 if this bull flag breaks to the upside.
SUPN LongMonthly trend change on wave trend indicator. 4 hour chart looks strong. VIX oversold signal screaming oversold. What's not to like?
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0LB2 is 28.8 USD — it has decreased by 4.87% in the past 24 hours. Watch SUPERNUS PHARMACEUTICALS INC USD0.001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange SUPERNUS PHARMACEUTICALS INC USD0.001 stocks are traded under the ticker 0LB2.
SUPERNUS PHARMACEUTICALS INC USD0.001 is going to release the next earnings report on Aug 6, 2024. Keep track of upcoming events with our Earnings Calendar.
0LB2 stock is 5.12% volatile and has beta coefficient of 0.94. Track SUPERNUS PHARMACEUTICALS INC USD0.001 stock price on the chart and check out the list of the most volatile stocks — is SUPERNUS PHARMACEUTICALS INC USD0.001 there?
SUPERNUS PHARMACEUTICALS INC USD0.001 revenue for the last quarter amounts to 143.64 M USD despite the estimated figure of 145.83 M USD. In the next quarter revenue is expected to reach 148.85 M USD.
Yes, you can track SUPERNUS PHARMACEUTICALS INC USD0.001 financials in yearly and quarterly reports right on TradingView.
0LB2 stock has fallen by 5.42% compared to the previous week, the month change is a 9.15% fall, over the last year SUPERNUS PHARMACEUTICALS INC USD0.001 has showed a 19.63% decrease.
0LB2 net income for the last quarter is 124.00 K USD, while the quarter before that showed 1.18 M USD of net income which accounts for −89.45% change. Track more SUPERNUS PHARMACEUTICALS INC USD0.001 financial stats to get the full picture.
Today SUPERNUS PHARMACEUTICALS INC USD0.001 has the market capitalization of 1.65 B, it has increased by 1.19% over the last week.
No, 0LB2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0LB2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SUPERNUS PHARMACEUTICALS INC USD0.001 stock right from TradingView charts — choose your broker and connect to your account.
0LB2 reached its all-time high on Jun 29, 2018 with the price of 60.8 USD, and its all-time low was 21.8 USD and was reached on Dec 14, 2020. View more price dynamics on 0LB2 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
As of May 10, 2024, the company has 652.00 employees. See our rating of the largest employees — is SUPERNUS PHARMACEUTICALS INC USD0.001 on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SUPERNUS PHARMACEUTICALS INC USD0.001 technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SUPERNUS PHARMACEUTICALS INC USD0.001 stock shows the sell signal. See more of SUPERNUS PHARMACEUTICALS INC USD0.001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SUPERNUS PHARMACEUTICALS INC USD0.001 future price: according to them, 0LB2 price has a max estimate of 43.00 USD and a min estimate of 38.00 USD. Watch 0LB2 chart and read a more detailed SUPERNUS PHARMACEUTICALS INC USD0.001 stock forecast: see what analysts think of SUPERNUS PHARMACEUTICALS INC USD0.001 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SUPERNUS PHARMACEUTICALS INC USD0.001 EBITDA is 90.62 M USD, and current EBITDA margin is 16.17%. See more stats in SUPERNUS PHARMACEUTICALS INC USD0.001 financial statements.